Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas

被引:79
作者
Bechrakis, NE
Bornfeld, N
Zöller, I
Foerster, MH
机构
[1] Free Univ Berlin, Klinikum Benjamin Franklin, Dept Ophthalmol, D-12200 Berlin, Germany
[2] Univ Essen Gesamthsch, Dept Ophthalmol, Essen, Germany
关键词
D O I
10.1016/S0161-6420(02)01273-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare iodine 125 (I-125) plaque brachytherapy with transscleral tumor resection (TTR) of large uveal melanomas. Design: Retrospective, nonrandomized, comparative, interventional study. Participants: Two hundred thirty-seven patients with large uveal melanomas. Intervention: One hundred fifty-two uveal melanoma patients were treated with I-125 brachytherapy and 85 patients were treated with TTR. Patients were matched according to age, tumor size, and tumor location. Eighteen patients treated with I-125 brachytherapy and 36 patients treated with TTR were eligible for the matched group comparison. The mean patient age was 40.5 years, mean tumor height was 9.4 mm, and mean largest tumor diameter was 14.5 mm. The mean distance of the posterior tumor margin to the optic disc was 9.9 mm and to the fovea was 9.4 mm. The mean follow-up was, 27.1 months. Main Outcome Measures: Final visual acuity, incidence of secondary glaucoma, secondary enucleation, and metastatic rates. Results: Visual acuity of 20/200 or better was retained in 61.1 % of patients after TTR and 5.6% of patients after I-125 brachytherapy (P < 0.0009). The incidence of secondary glaucoma was higher after I-125 brachytherapy (33.3%) than after TTR (5.6%; P = 0.03). No difference was found with respect to eye retention (P = 0.3) and mortality rates (P = 0.9). Conclusions: Patients with large melanomas eligible for TTR retain a better visual function and have a lower incidence of secondary glaucoma than those treated by I-125 brachytherapy. (C) 2002 by the American Academy of Ophthalmology.
引用
收藏
页码:1855 / 1861
页数:7
相关论文
共 20 条
[1]  
AUGSBURGER JJ, 1990, OPHTHALMIC SURG LAS, V21, P682
[2]  
AUGSBURGER JJ, 1986, ARCH OPHTHALMOL-CHIC, V104, P655
[3]  
Bornfeld N, 1997, FRONT RADIAT THER ON, V30, P97
[4]   5-YEAR FOLLOW-UP OF HELIUM ION THERAPY FOR UVEAL MELANOMA [J].
CHAR, DH ;
CASTRO, JR ;
KROLL, SM ;
IRVINE, AR ;
QUIVEY, JM ;
STONE, RD .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (02) :209-214
[5]  
CRUESS AF, 1984, OPHTHALMOLOGY, V91, P131
[6]  
Damato B, 1997, FRONT RADIAT THER ON, V30, P123
[7]  
Damato B E, 1993, Bull Soc Belge Ophtalmol, V248, P11
[8]   PREDICTIVE FACTORS OF VISUAL OUTCOME AFTER LOCAL RESECTION OF CHOROIDAL MELANOMA [J].
DAMATO, BE ;
PAUL, J ;
FOULDS, WS .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1993, 77 (10) :616-623
[9]   Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection [J].
Damato, BE ;
Paul, J ;
Foulds, WS .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1996, 80 (02) :102-108
[10]  
DIENERWEST M, 1993, CONTROL CLIN TRIALS, V14, P362